Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY.
BROMPHENIRAMINE MALEATE vs CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily fecal (80%) and renal (11%) as unchanged drug.
Category C
Category A/B
Antihistamine
Antihistamine